These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 23702810

  • 1. Efficacy of infliximab in intestinal Behçet's disease: a Korean multicenter retrospective study.
    Lee JH, Cheon JH, Jeon SW, Ye BD, Yang SK, Kim YH, Lee KM, Im JP, Kim JS, Lee CK, Kim HJ, Kim EY, Kim KO, Jang BI, Kim WH.
    Inflamm Bowel Dis; 2013 Aug; 19(9):1833-8. PubMed ID: 23702810
    [Abstract] [Full Text] [Related]

  • 2. Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet's Disease Treated with Infliximab.
    Zou J, Ji DN, Cai JF, Guan JL, Bao ZJ.
    Dig Dis Sci; 2017 Feb; 62(2):441-447. PubMed ID: 28044230
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study.
    Lee KM, Jeen YT, Cho JY, Lee CK, Koo JS, Park DI, Im JP, Park SJ, Kim YS, Kim TO, Lee SH, Jang BI, Kim JW, Park YS, Kim ES, Choi CH, Kim HJ, IBD study Group of Korean Association for the Study of Intestinal Diseases.
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1829-33. PubMed ID: 23829336
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab).
    Lee JH, Kim TN, Choi ST, Jang BI, Shin KC, Lee SB, Shim YR.
    Korean J Intern Med; 2007 Mar; 22(1):24-7. PubMed ID: 17427642
    [Abstract] [Full Text] [Related]

  • 11. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease.
    Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A.
    Int Ophthalmol; 2005 Jun; 26(3):83-92. PubMed ID: 17031510
    [Abstract] [Full Text] [Related]

  • 12. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.
    Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL.
    Gut; 2001 Nov; 49(5):725-8. PubMed ID: 11600479
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
    Keino H, Okada AA, Watanabe T, Taki W.
    Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.